相关实验视频
Updated: Jun 27, 2025
07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.0K
肠道微生物群与便秘的联系:来自两样双向孟德尔随机化研究的见解
Jiajie Zhou1, Xiaoming Yuan1, Yeliu Liu1
1Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu Province, China.
Microbial pathogenesis
|April 30, 2024
概括
肠道微生物群的不平衡,特别是较低的Coprococcus和较高的Bacteroidetes,与便秘风险有关. 这项研究表明,肠道细菌会影响便秘,而不是相反.
科学领域:
- 微生物组研究的研究.
- 胃肠病学 胃肠病学
- 遗传流行病学遗传流行病学
背景情况:
- 肠道微生物群失调与包括便秘在内的各种健康问题有关.
- 以前的研究表明,肠道微生物失衡与便秘风险之间存在关联.
研究的目的:
- 通过双向孟德尔随机化 (MR) 来研究肠道微生物群组成和便秘之间的因果关系.
- 确定连接肠道微生物群和便秘的遗传机制.
主要方法:
- 一项两样双向MR研究,利用来自MiBioGen联盟的肠道微生物群数据和来自IEU数据库的便秘数据.
- 分析包括逆方差加权 (IVW),MR-Egger和加权中位数方法.
- 敏感性分析使用了科克兰的Q测试,MR-Egger拦截,MR-PRESSO和Leave-one-out分析,以确保结果的有效性.
主要成果:
- 预先的MR分析表明,Coprococcus繁多和便秘之间存在负相关性 (OR=0.74,p=0.0001).
- 前进的MR分析显示,细菌菌种繁多和便秘之间存在正相关性 (OR=1.22,p=0.04).
- 没有发现便秘对肠道微生物群组成有显著影响.
结论:
- 增加的Coprococcus和减少的Bacteroidetes丰富性与降低便秘易感性有遗传联系.
- 研究结果支持这样一个假设:肠道微生物群的变化有助于便秘的发展.
更多相关视频
08:14A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
8.8K
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
9.6K
相关概念视频
01:23Anatomy of the Intestines
71.8K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
71.8K
01:21Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160